Connect with us

Technology

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

Published

2 months ago

on

BEIJING, July 19, 2024 /PRNewswire/ — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. For details, please visit below link:

https://www.sec.gov/Archives/edgar/data/1962738/000110465924080958/tm2419826d1_6k.htm

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market, leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. More information on CASI is available at www.casipharmaceuticals.com.

CASI Forward-Looking Statements:

This announcement and the current report on Form 6-K contain forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the business outlook and quotations from management in this announcement and the current report on Form 6-K, as well as the Company’s strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on The Nasdaq Capital Market if we fail to satisfy applicable continued listing standards; the volatility in the market price of our ordinary shares; the risk of substantial dilution of existing shareholders in future share issuances; the difficulty of executing our business strategy on a global basis including China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; legal or regulatory developments in China that adversely affect our ability to operate in China, our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency, PRC National Medical Products Administration, or other regulatory authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; the risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the risks associated with our product candidates, and the risks associated with our other early-stage products under development; the risk that result in preclinical and clinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; our ability to protect our intellectual property rights; the lack of success in the clinical development of any of our products; and our dependence on third parties; the risks related to our dependence on Juventas to conduct the clinical development of CNCT19 and to partner with us to co-market CNCT19; risks related to our dependence on Juventas to ensure the patent protection and prosecution for CNCT19; risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); risks relating to interests of our largest shareholder and our Chairman and CEO that differ from our other shareholders; and risks related to the development of a new manufacturing facility by CASI Pharmaceuticals (Wuxi) Co., Ltd. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided herein is as of the date of this announcement and the current report on Form 6-K, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

EVOMELA® is proprietary to Acrotech Biopharma Inc. and its affiliates. FOLOTYN® is proprietary to Acrotech Biopharma Inc and its affiliates.

COMPANY CONTACT:
Rui Zhang
CASI Pharmaceuticals, Inc.
240.864.2643
ir@casipharmaceuticals.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-reports-development-relating-to-its-disputes-with-juventas-302201852.html

SOURCE CASI Pharmaceuticals, Inc.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Chinese brand Desman ranked the top globally in high-end smart locks sales, three major agencies announced

Published

56 mins ago

on

September 27, 2024

By

BEIJING, Sept. 27, 2024 /PRNewswire/ — Hangzhou, Zhejiang province-based Desman (China) Machinery & Electronic Co Ltd has become the global leader in sales of high-end smart locks. Three leading domestic and international agencies jointly announced that the company has ranked the top in the segment in China and the world for three consecutive years for overall sales.

Desman held a conference about the brand’s growth momentum on Sept 25 in Beijing. At the event, three agencies, which are China Daily Hardware Technology Development Center (approved by the State Scientific and Technological Commission), consulting firm Euromonitor International, and Beijing-based market consultancy Shangpu Group, jointly certified that Desman’s high-end smart locks have ranked the top in domestic and global sales for three consecutive years. The brand was also recognized with the certification of “world-leading core technologies”.

During the event, the three agencies presented their comprehensive research results of domestic and international smart locks markets. Based on data from national market research conducted over the past three years (2021-2023), Desman’s high-end smart locks continuously ranked the top for sales in China. Besides, global market research taken over the same period showed that Desman took the top spot for sales volume and market share in the global high-end smart locks market for three straight years.

The certification of “world-leading core technologies” was a result based on extensive interviews with industry experts and an assessment of the core technologies used throughout the lifecycle of the products. This evaluation also included a comparative analysis of major smart locks companies in terms of technological advancement, market recognition, production capacity and sales.

Meanwhile, London-based World Record Certification Agency (WRCA) awarded Desman with the certification of “world’s most outstanding smart lock with ultra-high fingerprint recognition rate” (Desman GPTfinger fingerprint recognition technology). Third-party testing confirmed that the fingerprint module applying Desman’s GPTfinger technology achieved a false acceptance rate of only 0.00099% and a false rejection rate of 0.86379%.

During the event, WRCA certification officer Maksim Kriukov said Desman leads the smart locks industry with its groundbreaking GPTfinger fingerprint recognition technology. It enabled the products to embrace a new era of GPT algorithm-based recognition, and this advancement addresses the challenges faced by a small group of people with difficulties in fingerprint recognition.

In addition, the event witnessed the official signing between Desman and its partner about Desman’s fourth global joint laboratory in Phoenix, Arizona, the United States, and thus completing its global network of building four labs. Those labs are strategically located in diverse environments, including the desert climate of Phoenix; the extreme high temperature climate of Dubai, the United Arab Emirates; the typhoon-prone climate of Taiwan, China; and the moderate climate of Hangzhou, Zhejiang province, China. Together, the labs form a comprehensive testing network and enable Desman products to go through rigorous reliability tests in extreme conditions, ensuring long-term stability of the smart locks products across regions.

Zhu Zhiling, chairman and CEO of Desman, said at the event that the success that Desman has achieved is a snapshot of China’s smart locks industry, and an indication of China’s technological advancements.

“Guided by our vision of ‘technology makes life simpler’, Desman will continue to drive innovation in the smart locks industry and ensure that every household has access to advanced smart locks solutions,” Zhu said.

View original content to download multimedia:https://www.prnewswire.com/news-releases/chinese-brand-desman-ranked-the-top-globally-in-high-end-smart-locks-sales-three-major-agencies-announced-302260871.html

SOURCE Desman (China)

Continue Reading

Technology

Medius named Customer Favorite by Spend Matters

Published

56 mins ago

on

September 27, 2024

By

JACKSONVILLE, Fla., Sept. 27, 2024 /PRNewswire/ — Medius, a leading provider of AP Automation and wider Spend Management solutions, today announced that it has earned three prestigious SolutionMap Customer Favorite badges from Spend Matters:

Customer Favorite – Supplier Management
Customer Favorite – Contract Lifecycle Management
Customer Favorite – eProcurement

Medius is among 93 vendors in the Fall 2024 SolutionMap and TechMatchSM procurement technology rankings. Each of the vendors in the SolutionMap process undergo rigorous functionality and capability assessment with 500+ RFI requirements across 15 procurement technology solutions with mandatory demos and impartial, anonymized customer ratings.

Vendors with the highest number of top scores from their customers’ surveys earn the Customer Favorite badges.

“We’ve designed SolutionMap to aid the practitioner so they may better understand and analyze the customer experiences, market developments and technological innovation of the myriad solution providers by process competency,” said Jason Busch, Founder and CEO of Spend Matters.

“We are excited to see Medius solutions awarded as customer favorites in so many areas of Medius’ spend management suite. We continue to deliver incremental innovations that help them save time, reduce risk, improve operations, and add more value to their procure-to-pay processes and customer clearly love our work in the independent feedback they provide through the SolutionMap process,” said Daniel Ball, Chief Product Officer at Medius.

For more information, please contact:
Dan Bird, Fight or Flight for Medius
Dan.Bird@fightflight.co.uk +44 7885 670798 / Medius@fightflight.co.uk +44 330 133 0985

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medius/r/medius-named-customer-favorite-by-spend-matters,c4043783

 

View original content:https://www.prnewswire.co.uk/news-releases/medius-named-customer-favorite-by-spend-matters-302260873.html

Continue Reading

Technology

HORIBA India and Dumarey Group join hands to provide engineering services for the design and development of Internal Combustion Engines (ICE, H2-ICE), transmission and electrical vehicles for Indian market

Published

56 mins ago

on

September 27, 2024

By

NEW DELHI, Sept. 27, 2024 /PRNewswire/ — HORIBA India, a subsidiary of The Japanese conglomerate HORIBA, Ltd., and Dumarey Group joined hands for engineering consultancy on the design and development of Internal Combustion Engines (including hydrogen-powered applications, both dual fuel and 100% H2), transmissions and electrical vehicles for Indian customers.

HORIBA India, with a wide range of analytical and measurement solutions from its parent company HORIBA, Ltd., and Dumarey Group, with its specialization in engineering, development, integration and sale of hydrogen and diesel technologies, shall bring to the table their respective knowhow and expertise on hydrogen-powered solutions, decarbonizing solution, engineering consultancy on development projects and testing facilities for the Indian market.

An official MoU exchange took place at the Dumarey facility in Torino, Italy, in July 2024. The MoU was signed between Dr. Rajeev Gautam, Corporate Officer – HORIBA, Ltd., Japan and President – HORIBA India, and Mr. Pierpaolo Antonioli, CEO – Dumarey Propulsion Solutions and CTO Dumarey Group, for this partnership.

“The partnership will open up new horizons for development and testing of conventional and hydrogen fuelled internal combustion engines,” quotes Dr. Rajeev Gautam.

Pierpaolo Antonioli, CTO Dumarey Group, says: “This collaboration marks a significant step forward in our commitment to pioneering sustainable and innovative propulsion solutions. By combining our expertise with HORIBA’s advanced analytical capabilities, we are ready to deliver cutting-edge technologies that will drive the future of mobility in India.”

About HORIBA India

HORIBA India, a wholly owned subsidiary of The HORIBA Group, based in Kyoto, Japan, is a world leader in analytical testing and research equipment, operating across the globe since its inception in 1953.

Headquartered in New Delhi, HORIBA India started its direct operations in the country in 2006 and since then has evolved to a company of 500+ employees, with a presence in PAN India and SAARC nations.

HORIBA provides unique analysis and measurement technologies and solutions for optimizing the operation of alternative energy carriers, such as hydrogen (H2) and ammonia (NH3), by combining ‘global network’ x ‘measurement technology’ x ‘engineering’.

About Dumarey Group

The Dumarey Group is an independent provider specializing in the development, integration, and production of cutting-edge propulsion systems, including transmissions and engines. With extensive expertise in engineering, manufacturing, and technological integration, backed by proven methods and processes, Dumarey Group delivers comprehensive ‘turnkey’ solutions tailored to industry needs. Its product portfolio encompasses the design of advanced propulsion systems, state-of-the-art control technologies, transmissions for passenger and commercial vehicles, injectors, after-treatment technologies, kinetic energy recovery systems, and second-life battery solutions. The company operates across seven locations in Europe and Asia, employing around 3,000 people and generating annual revenues of approximately 1 billion euros. Founded in 1983, the Dumarey Group was known as PUNCH until September 2023.

Press contact HORIBA India
Kanika Thakur (Lead – Corporate Communications)
Mobile: +91 96060 91711
Email: kanika.thakur@horiba.com, cco.hin@horiba.com 

Press contact Dumarey Group 
Manuela Seia
Mobile: +39 348 48 30 559
Email: manuela.seia@dumarey.com

Photo: https://mma.prnewswire.com/media/2517381/Group_photograph_of_officials.jpg

 

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/horiba-india-and-dumarey-group-join-hands-to-provide-engineering-services-for-the-design-and-development-of-internal-combustion-engines-ice-h2-ice-transmission-and-electrical-vehicles-for-indian-market-302260876.html

Continue Reading

Trending